428,310 Shares in Hologic, Inc. (HOLX) Purchased by Mawer Investment Management Ltd.
Mawer Investment Management Ltd. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 428,310 shares of the medical equipment provider’s stock, valued at approximately $17,025,000. Mawer Investment Management Ltd. owned about 0.16% of Hologic at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Piedmont Investment Advisors LLC purchased a new stake in shares of Hologic during the 2nd quarter worth about $127,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Hologic during the 1st quarter worth about $146,000. Synovus Financial Corp purchased a new stake in shares of Hologic during the 1st quarter worth about $164,000. Granite Springs Asset Management LLC purchased a new stake in shares of Hologic during the 2nd quarter worth about $206,000. Finally, IBM Retirement Fund purchased a new stake in shares of Hologic during the 1st quarter worth about $227,000. 93.34% of the stock is owned by institutional investors.
HOLX has been the subject of a number of research reports. TheStreet upgraded Hologic from a “c” rating to a “b” rating in a report on Tuesday, July 31st. BTIG Research reiterated a “buy” rating and set a $44.00 target price on shares of Hologic in a report on Sunday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $43.00 price target (down previously from $50.00) on shares of Hologic in a report on Tuesday, May 1st. BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. Finally, Jefferies Financial Group restated a “buy” rating and issued a $50.00 price target on shares of Hologic in a report on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $45.33.
Hologic (NASDAQ:HOLX) last released its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.02. The company had revenue of $824.00 million during the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. sell-side analysts forecast that Hologic, Inc. will post 2.24 earnings per share for the current fiscal year.
In other news, insider Peter J. Valenti III sold 10,107 shares of the stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total transaction of $389,321.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.88% of the company’s stock.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Article: New Google Finance Tool and Screening Stocks
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.